HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $6 Price Target

Benzinga · 12/30/2025 15:35
HC Wainwright & Co. analyst Matthew Keller reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $6 price target.